Low Testosterone in Men: A Diagnosis, a Symptom, or Just Good Marketing?

From testosterone subscriptions to performance-enhancing drugs, are we confusing hormonal optimisation with better health?

Spend ten minutes on social media and you’d be forgiven for thinking testosterone deficiency is an epidemic among middle-aged men. The adverts promise energy, focus, muscle, better sex and a return to your twenties.

I’ve been thinking about testosterone from two directions lately. As a GP, I’m increasingly seeing the commercialisation of testosterone replacement and the misinformation around it. This was one of the themes in a webinar I attended recently on hypogonadism. Separately, my reading around on testosterone in women as part of my menopause qualification has meant a lot of reviewing evidence, and I’ve been struck by how similar the marketing is for both sexes. This piece is about men: when treatment is justified, where the evidence is thinner, and whether “optimisation” is sometimes more marketing than medicine.

Some men do have genuine symptoms that deserve investigation. Many others have seen an advert suggesting that tiredness, weight gain, low motivation or simply getting older means a hormone problem. Those symptoms are common and have plenty of other explanations. There’s a real difference between recognising a medical condition and creating a market for treating a lab result.

Is testosterone deficiency really increasing?

Testosterone production is driven by the hypothalamus, pituitary and testes. Levels tend to drift down with age, at very different rates, and are affected by body fat, metabolic disease and general health. “Male menopause” is a misleading phrase, because there’s no universal, fairly abrupt drop in middle-aged men comparable to the menopause in women.

True hypogonadism is still an important diagnosis. It can cause reduced libido, erectile difficulties, loss of morning erections and lower bone density. The hard part is telling those men apart from men whose symptoms come from poor sleep, stress, obesity, medication or other illness.

The problem with commercial testing

More and more commercial providers offer testosterone testing, usually with a symptom questionnaire and the prospect of ongoing replacement. Not all of it is poor quality. Some follow established guidance and use accredited laboratories. But some of the marketing deserves scrutiny.

First, questionnaires about tiredness, mood, concentration and sexual performance can’t diagnose testosterone deficiency. Even the established ones have limited accuracy, so it’s fair to ask whether a commercially promoted one has been validated at all.

Second, an accurate result can still mislead if the sample was taken at the wrong time. The Society for Endocrinology and the Association for Clinical Biochemistry and Laboratory Medicine recommend testing before 11 am, after an overnight fast and a normal night’s sleep, when the man is otherwise well.[1] Shift workers may need specialist advice. A low result should be repeated on a separate morning.

Two properly timed results below 8 nmol/L with compatible symptoms strongly suggest hypogonadism. Results between 8 and 12 nmol/L need careful interpretation, and above 12 nmol/L it’s generally unlikely.[1] These are action thresholds rather than hard diagnostic lines. SHBG matters too, especially in men with obesity, where low SHBG can pull total testosterone down without a matching fall in free testosterone. A single borderline result should never automatically lead to a prescription.

The soldier back from exercise

Military primary care shows why context matters. We sometimes see soldiers asking for blood tests straight after a demanding exercise: hard physical work, little sleep, not enough food. Testosterone production can be temporarily suppressed under that kind of physical stress and low energy availability, much as in endurance athletes.

A test taken at that point tells us more about the last few weeks than about long-term testicular function. A low result doesn’t necessarily mean permanent dysfunction. Often the right answer is to get some proper food, sleep and recovery, then recheck. If we treat a temporary adaptation as permanent deficiency, we risk turning someone who just needed to recover into a long-term patient.

Primary or secondary?

Once deficiency is confirmed, the cause matters. In primary hypogonadism the testes can’t produce enough testosterone despite appropriate stimulation, so testosterone is low and LH (and often FSH) is raised. Causes include genetic conditions, testicular damage and previous chemotherapy. In secondary hypogonadism the hypothalamus or pituitary isn’t providing enough stimulation, so testosterone is low and LH and FSH are low or inappropriately normal.

Some causes are serious, pituitary disease among them. Others are potentially reversible, such as systemic illness, medication effects and significant energy deficiency. Fixing a reversible cause may restore production without any need for replacement, but assuming every case of secondary hypogonadism is lifestyle-related risks missing real pathology.

Middle-aged spread: cause or consequence?

Fat tissue contains aromatase, which converts testosterone to oestradiol. Obesity also brings insulin resistance, inflammation, lower SHBG and altered hypothalamic-pituitary signalling. A 2025 review by Muir and colleagues makes the point that obesity-related falls in testosterone are often functional and potentially reversible.[2] They describe proportionately lower testosterone and SHBG with normal LH and FSH as the pseudo-hypogonadism of obesity, rather than pathological deficiency. Substantial, sustained weight loss can bring testosterone back up.

So before prescribing for a middle-aged man who has put on weight, it’s worth asking whether improving his metabolic health might help both the symptoms and the hormones. Sometimes low testosterone is a result of poor metabolic health, not the cause.

What happens when you stop?

Many patients underestimate what replacement does to their own hormone production. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis through negative feedback. LH and FSH fall, the testes get less stimulation, endogenous testosterone drops, and sperm production can be severely impaired or stop. This can start within weeks, though how much and how quickly depends on the preparation and dose.

A man who started treatment on borderline results and vague symptoms may find that stopping leaves him temporarily more deficient than he was before. Fatigue, low libido and low mood can appear or worsen while the axis recovers. Some recover within months; others take much longer. Sperm production can take longer still. A 2025 review in Nature Reviews Urology notes that although it often returns, recovery is variable and may be protracted, particularly in men with underlying axis dysfunction, and a recovered sperm count doesn’t guarantee previous fertility.[4]

Data from male hormonal contraception studies suggest around 67% of men get back to at least 20 million/mL within six months, and 90% within twelve.[4] Those men were mostly healthy and treated for limited periods, so the figures can’t safely be applied to older men on long-term testosterone.

Some men with genuine permanent hypogonadism will rightly need lifelong treatment. My concern is with those whose original suppression was potentially reversible. Difficulty stopping doesn’t mean everyone who starts testosterone will need it for life, but starting is easy and stopping can be much harder. That’s especially relevant for younger men who may want children. Exogenous testosterone shouldn’t be used in men actively seeking fertility, who need specialist assessment for fertility-preserving options.

What about the other risks?

Testosterone isn’t a harmless lifestyle supplement. Recognised adverse effects include raised haematocrit, acne, breast symptoms and possible worsening of untreated severe obstructive sleep apnoea. Prostate health needs proper assessment. The evidence doesn’t show that appropriately prescribed testosterone causes prostate cancer, but treatment is generally contraindicated in active prostate cancer outside carefully selected specialist settings.

The large TRAVERSE trial (2023) found testosterone gel non-inferior to placebo for major adverse cardiovascular events in men aged 45–80 with confirmed hypogonadism and existing cardiovascular disease or raised risk.[3] That doesn’t establish safety for every population, formulation or duration. Atrial fibrillation, pulmonary embolism and acute kidney injury were all more common in the treatment group. Cardiovascular reassurance shouldn’t be mistaken for proof that treatment is risk-free.

What did the Enhanced Games teach us?

The first Enhanced Games, in Las Vegas in May 2026, were meant to show what athletes could do with medically supervised performance-enhancing drugs and no conventional anti-doping rules. The publicity hinted that human limits might be dramatically surpassed. The reality was far less spectacular.

Only one performance beat an official world-record time: Kristian Gkolomeev’s 20.81 seconds in the men’s 50 m freestyle. Even that came in a swimsuit banned from conventional elite competition, so it wasn’t a ratified World Aquatics record. A peer-reviewed analysis in Physiological Reports compared 42 athletes’ results with world records and their own previous bests.[5] There were 19 new personal bests, but on average performances were worse than athletes’ previous bests.

That doesn’t mean anabolic steroids don’t work. There’s good evidence they increase muscle mass and strength. Nor can the Games tell us what these athletes would have achieved without the drugs; this was an observational comparison, not a randomised trial. But performance depends on genetics, technique, years of training, nutrition, recovery, mental resilience and opportunity, and drugs can’t simply stand in for those.

The parallel with marketing testosterone to middle-aged men is hard to miss. Both sell the idea of a pharmacological shortcut to performance, vitality and wellbeing.

Is testosterone becoming a subscription business?

In the NHS, men needing long-term replacement usually get transdermal gels or long-acting intramuscular injections. Testosterone undecanoate, for example, is given roughly every 10–14 weeks once on maintenance. Some commercial providers offer weekly or twice-weekly formulations within subscription packages covering blood tests, reviews and ongoing prescription charges.

There can be legitimate reasons for smaller, more frequent doses, including less fluctuation in levels, so frequent dosing isn’t inherently wrong. But it’s reasonable to ask about the incentives in a model that earns recurring income from continued prescribing, testing and monitoring. I’m not suggesting finances drive prescribing decisions. Patients do deserve transparency about costs, alternative formulations, the clinical indication, and how hard it may be to stop. And all formulations need proper monitoring.

The question should always be whether treatment is clinically necessary, not whether a borderline result can be turned into a long-term customer.

A prescription or a change in direction?

Men with persistent symptoms suggestive of deficiency deserve a proper assessment, and genuine hypogonadism is an important, treatable condition. Before prescribing, we should think about sleep, activity, nutrition, psychological wellbeing, medication, metabolic health and other medical conditions. Where testing is indicated, it should be done properly, repeated if low, and interpreted in context. Confirmed deficiency needs investigation to separate primary from secondary causes. For men with obesity-related functional suppression, improving metabolic health may be the best first step, and possibly a conversation about weight loss medication.

Testosterone remains an important treatment for men who genuinely need it. It isn’t an anti-ageing miracle, a substitute for training and recovery, or a fix for the challenges of middle age. A low result should start a clinical investigation, not automatically a lifelong prescription.

References

1. Jayasena, C. N., et al. (2023). Standardising the biochemical confirmation of adult male hypogonadism: A joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine. Annals of Clinical Biochemistry, 60(4), 223–227. https://doi.org/10.1177/00045632231179022

2. Muir, C. A., Wittert, G. A., & Handelsman, D. J. (2025). Approach to the patient: Low testosterone concentrations in men with obesity. The Journal of Clinical Endocrinology & Metabolism, 110(9), e3125–e3130. https://doi.org/10.1210/clinem/dgaf137

3. Lincoff, A. M., et al. (2023). Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine, 389(2), 107–117. https://doi.org/10.1056/NEJMoa2215025

4. Naelitz, B. D., et al. (2025). Testosterone replacement therapy and spermatogenesis in reproductive age men. Nature Reviews Urology, 22, 703–719. https://doi.org/10.1038/s41585-025-01032-8

5. Azevedo, R. A., et al. (2026). Enhanced but not superior: Performance outcomes from the inaugural enhanced games. Physiological Reports, 14(19), e71123. PMID: 42810982. https://doi.org/10.14814/phy2.71123

This article provides general health information and is not a substitute for individual medical assessment.

Comments

Leave a Reply